(S)-(+)-Ibuprofen - CAS 51146-56-6
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
(S)-(+)-Ibuprofen
Catalog Number:
51146-56-6
Synonyms:
(S)-Ibuprofen
CAS Number:
51146-56-6
Description:
Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activity; A non-steroidal anti-inflammatory drug
Molecular Weight:
206.28
Molecular Formula:
C13H18O2
Quantity:
Grams-Kilos
Quality Standard:
In-house
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC(C)CC1=CC=C(C=C1)C(C)C(=O)O
InChI:
1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/t10-/m0/s1
InChIKey:
HEFNNWSXXWATRW-JTQLQIEISA-N
Targets:
Cox-2 | COX
Chemical Structure
CAS 51146-56-6 (S)-(+)-Ibuprofen

Related Cox-2 Products


CAS 53164-05-9 Acemetacin

Acemetacin
(CAS: 53164-05-9)

COX inhibitor; A non-steroidal anti-inflammatory drug

CAS 189954-96-9 Firocoxib

Firocoxib
(CAS: 189954-96-9)

A selective COX-2 inhibitor

BMS-347070
(CAS: 197438-73-6)

BMS-347070 is a COX-2 inhibitor, initially developed for the treatment for Colorectal cancer.

CAS 853-34-9 Kebuzone

Kebuzone
(CAS: 853-34-9)

Kebuzone is a non-steroidal anti-inflammatory drug. It also has analgesic, antipyretic, and platelet-inhibitory activities. Kebuzone is a cyclooxygenase inhibit...

CAS 61618-27-7 Amfenac Sodium monohydrate

Amfenac Sodium monohydrate
(CAS: 61618-27-7)

A potent inhibitor of both COX-1 and COX-2 with IC50 of 0.25 and 0.15 μM

CAS 220991-20-8 Lumiracoxib

Lumiracoxib
(CAS: 220991-20-8)

A novel, selective COX-2 inhibitor; Phase 4

CAS 23513-14-6 Gingerol

Gingerol
(CAS: 23513-14-6)

Gingerol is the active constituent of fresh ginger. It is bioactive compound found in ginger (Zingiber officinale) with antioxidant activity, which functions as...

CAS 261766-32-9 N-(2-phenylethyl)-Indomethacin amide

N-(2-phenylethyl)-Indomethacin amide
(CAS: 261766-32-9)

A potent elective reversible inhibitors of COX-2

CAS 103-90-2 Acetaminophen

Acetaminophen
(CAS: 103-90-2)

A selective COX-2 inhibitor

CAS 53-86-1 Indomethacin

Indomethacin
(CAS: 53-86-1)

A nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively

COX-2 Inhibitor I
(CAS: 416901-58-1)

An inhibitor of Cox-2

CAS 116686-15-8 FK 3311

FK 3311
(CAS: 116686-15-8)

A selective COX-2 inhibitor

CAS 162011-90-7 Rofecoxib

Rofecoxib
(CAS: 162011-90-7)

A COX-2 inhibitor( IC50s = 26 nM and > 50 µM in human osteosarcoma cells )

CAS 51146-56-6 (S)-(+)-Ibuprofen

(S)-(+)-Ibuprofen
(CAS: 51146-56-6)

Be capable of inhibiting cyclooxygenase (COX) at clinically relevant concentrations; As an enantiomer of (R)-(-)-Ibuprofen, it more potently inhibits COX activi...

CAS 156897-06-2 Licofelone

Licofelone
(CAS: 156897-06-2)

A dual inhibitor of COX-1/COX-2 and 5-LO

CAS 501-36-0 Resveratrol

Resveratrol
(CAS: 501-36-0)

Resveratrol (also known as SRT-501) is a phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resv...

FR-188582
(CAS: 189699-82-9)

FR-188582, with anti-inflammatory and ulcerogenic properties, is a highly selective inhibitor of COX-2 with IC50= 0.017 microM.

CAS 13710-19-5 Tolfenamic Acid

Tolfenamic Acid
(CAS: 13710-19-5)

A COX-2 inhibitor with IC50 of 0.2 μM

CAS 78281-72-8 Nepafenac

Nepafenac
(CAS: 78281-72-8)

An inhibitor of COX-1 and COX-2

CAS 15307-86-5 Diclofenac

Diclofenac
(CAS: 15307-86-5)

A non-selective COX inhibitor with IC50 of 60 and 220 nM for ovine COX-1 and -2, respectively.

Reference Reading


1.Influence of temperature on toxicity of single pharmaceuticals and mixtures, in the crustacean A. desmarestii.
Nieto E1, Hampel M2, González-Ortegón E3, Drake P4, Blasco J4. J Hazard Mater. 2016 Mar 24;313:159-169. doi: 10.1016/j.jhazmat.2016.03.061. [Epub ahead of print]
Lethal and sublethal responses of the shrimp Atyaephyra desmarestii exposed to three pharmaceutical compounds, Diclofenac (DF), Ibuprofen (IB) and Carbamazepine (CBZ), individually and in mixtures, were evaluated under two temperature scenarios. LC50 (96h) values were obtained individually at 20° and 25°C. At 25°C, mortality in binary and ternary mixtures is higher than at 20°C. The toxicity of the mixtures was predicted on the basis of individual mortality data using two toxicity models: Concentration addition (CA) and Independent action (IA). Our results showed that neither CA nor IA unequivocally predicted the observed toxicity of binary and ternary mixtures. For sublethal toxicity, selected endpoints were: ingestion rate, osmoregulatory capacity and respiration rate. Regarding osmoregulatory capacity, no significant differences were found. The highest ingestion rates were recorded in organisms exposed at 25°C, irrespective of the compound, after 30 and 60min of exposure.
2.Active removal of ibuprofen by Money plant enhanced by ferrous ions.
Chehrenegar B1, Hu J2, Ong SL1. Chemosphere. 2016 Feb;144:91-6. doi: 10.1016/j.chemosphere.2015.08.060. Epub 2015 Sep 5.
In this study, the removal of ibuprofen (IBP), a pharmaceutical compound, from aqueous media by Money plant (Epipremnum aureum) was investigated. The effect of ferrous iron (Fe(2+)) on enhancing the IBP removal rate was also analyzed. The first-order removal rate constants showed higher values for lower IBP initial concentrations in the range of 0.20-0.28 d(-1) for an initial concentration of 125 μg L(-1) to 0.03-0.13 d(-1) for an initial concentration of 1000 μg L(-1). Introducing ferrous iron to the aqueous media enhanced the first-order removal rate constant up to 6.5 times in a 3 d time period. Along with the removal of IBP from the media, the endogenous concentration of H2O2 also decreased presumably by the production of hydroxyl radical (·OH). Reduction in the endogenous H2O2 concentration was recorded to be 38% and 98% in the absence and presence of Fe(2+) respectively in the first day and the H2O2 level remained considerably low until day 7 which then gradually increased slightly.
3.Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys.
Pelletier JP1, Martel-Pelletier J2, Rannou F3, Cooper C4. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S22-7. doi: 10.1016/j.semarthrit.2015.11.009. Epub 2015 Dec 2.
Non-steroidal anti-inflammatory drugs (NSAIDs) are at the cornerstone of treatment for osteoarthritis (OA). In recent years, the widespread use of oral NSAIDs has been called into question due to the appearance of significant upper gastrointestinal (GI) complications and cardiovascular (CV) adverse events (AEs). However, NSAIDs are non-homogeneous, and there are noticeable differences between them in AE risk for GI and CV events. Nevertheless, if properly prescribed oral NSAIDs can provide an effective and safe treatment for OA in real-life situations. The identification of patients with significant CV and/or GI risk is critical, and the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm provides guidance on appropriate treatments for OA patients with elevated risk. Among non-selective NSAIDs, ibuprofen and naproxen seem preferable to diclofenac, the latter being associated with higher CV risk.
4.Cysteine amide adduct formation from carboxylic acid drugs via UGT-mediated bioactivation in human liver microsomes.
Harada H, Toyoda Y, Endo T, Kobayashi M. Pharmazie. 2015 Oct;70(10):678-83.
Although chemical trapping has been widely used to evaluate cytochrome P450-mediated drug bioactivation, thus far, only a few in vitro-trapping studies have been performed on UDP-glucuronosyltransferase (UGT)-mediated drug bioactivation. In this study, we used cysteine (Cys) as trapping agent to gain new insights into the UGT-mediated bioactivation involving acyl glucuronides of carboxylic acid drugs. Diclofenac, ketoprofen and ibuprofen were incubated in human liver microsomes with UDPGA and Cys, followed by analysis using ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS). The N-acyl-Cys amide adduct of diclofenac was characterized by mass analysis and was detectable even in photodiode array analysis. Our data indicated that the formation of such adducts reflects the reactivity of the corresponding acyl glucuronides. In addition, it was suggested that the adduct formation requires an N-terminal Cys moiety with both a free amine and a free thiol group, from the results using various cysteine derivatives.